Scribe Therapeutics posts Q2 2026 $1.9M collaboration revenue, $6.5M net loss
Scribe Therapeutics reported Q2 2026 collaboration revenue of $1.9 million and a net loss of $6.5 million, or $2.62 per basic and diluted share. Cash, cash equivalents and marketable securities were $43.0 million as of June 30, 2026.
Scribe Therapeutics reported second-quarter 2026 results showing collaboration revenue of $1.9 million and a net loss of $6.5 million (or $2.62 per basic and diluted share).
Cash, cash equivalents, and marketable securities were $43.0 million as of June 30, 2026, and the company raised approximatel…